Fulgent Genetics stock rating upgraded to Buy at UBS on growth potential

Published 05/08/2025, 08:50
Fulgent Genetics stock rating upgraded to Buy at UBS on growth potential

Investing.com - UBS upgraded Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raised its price target to $30.00 from $20.00 as analyst coverage of the company changes hands. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 6.0x.

The investment bank sees potential upside in Fulgent’s Precision Diagnostics segment, which represents approximately 60% of total sales, citing share gain opportunities in what it describes as a more favorable reimbursement landscape.

UBS notes that the company’s Anatomic Pathology business, accounting for roughly 35% of sales, has begun to recover and is no longer diluting growth for the diagnostic testing firm.

The firm expects Fulgent to maintain approximately 10% revenue growth in 2025 and beyond, which it believes aligns more closely with broader specialty and oncology peers based on its analysis, while suggesting current valuation gives the company no credit for this growth trajectory.

UBS also indicates investors may reassess the value of Fulgent’s pharmaceutical assets when data from the FID-007 trial becomes available in 2026.

In other recent news, Fulgent Genetics reported its Q2 2025 earnings, revealing a revenue of $81.8 million, which exceeded the forecast of $76.21 million. Despite the revenue beat, the company reported an earnings per share (EPS) of $0.07, which fell short of the expected EPS of $-0.18. This EPS result marked a surprise of -138.89%. These earnings results highlight the company’s mixed performance, with strong revenue figures but a miss on the EPS front. Investors might find the revenue performance encouraging, although the EPS miss could be a point of concern. There were no updates on any mergers or acquisitions involving Fulgent Genetics. Additionally, there were no recent analyst upgrades or downgrades reported for the company. These developments provide a snapshot of Fulgent Genetics’ current financial standing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.